A 67-year-old male patient received immunotherapy with intravenous infusion of sintili-mab 200 mg once every 3 weeks due to postoperative recurrence of liver cancer, and the efficacy and tolerance was good. After 12 doses of sintilimab treatment, the patient developed a bright red skin rashes on the chest, abdomen, and extremities with itching. Oral loratadine and topical halometasone cream were given, and the rashes were improved slightly. The rashes did not spread in the next 2 doses of sintilimab treatment. But after the 3rd dose of continuing sintilimab, the patient suddenly developed a large-area rashes all over the body, which rapidly developed into blisters, ulcers, accompanied by oozing blood and fluid on the skin, itching, and pain. Drug eruptions were diagnosed, which was considered to be induced by sintilimab. The drug was stopped. After 1 week of treatments with intravenous infusion of methylprednisolone 60 mg once daily, anti-allergy, anti-infection, mucosal protection, and skin care, the rashes were repeated. Then the dose of methylprednisolone was increased, the rashes were still not relieved 1 week later, and gastrointesting bleeding occurred. After liver cancer surgery, the patient was accompanied by hypoproteinemia, liver dysfunction, and long-term high-dose glucocorticoid use. Therefore, despite active treatment measures, the patient still died of ineffective rescue.

A 67-year-old male patient received immunotherapy with intravenous infusion of sintili-mab 200 mg once every 3 weeks due to postoperative recurrence of liver cancer, and the efficacy and tolerance was good. After 12 doses of sintilimab treatment, the patient developed a bright red skin rashes on the chest, abdomen, and extremities with itching. Oral loratadine and topical halometasone cream were given, and the rashes were improved slightly. The rashes did not spread in the next 2 doses of sintilimab treatment. But after the 3rd dose of continuing sintilimab, the patient suddenly developed a large-area rashes all over the body, which rapidly developed into blisters, ulcers, accompanied by oozing blood and fluid on the skin, itching, and pain. Drug eruptions were diagnosed, which was considered to be induced by sintilimab. The drug was stopped. After 1 week of treatments with intravenous infusion of methylprednisolone 60 mg once daily, anti-allergy, anti-infection, mucosal protection, and skin care, the rashes were repeated. Then the dose of methylprednisolone was increased, the rashes were still not relieved 1 week later, and gastrointesting bleeding occurred. After liver cancer surgery, the patient was accompanied by hypoproteinemia, liver dysfunction, and long-term high-dose glucocorticoid use. Therefore, despite active treatment measures, the patient still died of ineffective rescue.

Objective:To explore the clinical effects of tuina therapy of Yinyang Ruyin combined with aromatherapy on insomnia and quality of life in patients receiving perichemotherapy for breast cancer.Methods:Totally 199 inpatients with insomnia who received perichemotherapy for breast cancer from June 2018 to December 2019 and met inclusion and exclusion criteria were selected and divided into the control group ( n=48) , the tuina therapy of Yinyang Ruyin group ( n=50) , the aromatherapy group ( n=52) , and the combined treatment group ( n=49) according to the computer-generated random sequence. Patients in the control group received routine care; patients in the tuina therapy of Yinyang Ruyin group received tuina therapy of Yinyang Ruyin on this basis; patients in the aromatherapy group received aromatherapy on this basis; patients in the combined treatment group received both tuina therapy of Yinyang Ruyin and aromatherapy. After 6 cycles of chemotherapy, Pittsburgh Sleep Quality Index (PSQI) , Hamilton Depression Scale (HAMD) , and Functional Assessment of Cancer Therapy: General (FACT-G) were used to evaluate the intervention effects of the four groups. Results:The amelioration rates of insomnia in the 3 and 6 chemotherapy cycles after the intervention of the tuina therapy of Yinyang Ruyin group, the aromatherapy group, and the combined treatment group were higher than that of the control group ( P<0.05) ; the amelioration rates of insomnia in the 3 and 6 chemotherapy cycles after the intervention of the combined treatment group was higher than those of the tuina therapy of control group, Yinyang Ruyin group and the aromatherapy group ( P<0.05) . The repeated measures analysis of variance showed that the main effects of intervention in the PSQI, HAMD, and FACT-G scores of the four groups were statistically different ( P<0.05) ; the time of main effects of PSQI, HAMD, and FACT-G scores was significantly different ( P<0.05) ; there was an interaction between the intervention factors of PSQI, HAMD, and FACT-G scores and the time factor ( P<0.05) . Conclusions:Tuina therapy of Yinyang Ruyin combined with aromatherapy can ameliorate the symptoms of insomnia and depression, thereby improving the quality of life of patients.